Star Therapeutics, which created two antibody-focused biotech startups with more in the works, has now reeled in a $90 million Series C.
The round, disclosed Tuesday morning, brings the Bay Area biotech’s total financing to more than $190 million since emerging from Westlake Village BioPartners in early 2022.
Star’s biotech…
Click here to view original post
